William G Wierda, MD, University of Texas MD Anderson Cancer Center

William G. Wierda, MD, discusses data from the phase 1 cohort of lisocabtagene maraleucel combined with ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia that was presented at the 19th International Workshop on CLL (iwCLL) held in September 2021.

An overview of prognostic models in chronic lymphocytic leukemia (CLL).

A discussion about prognostic factors in patients with newly diagnosed chronic lymphocytic leukemia (CLL).

Ehab Attallah, MD, provides an overview of molecular testing for patients with newly diagnosed chronic lymphocytic leukemia (CLL).